KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Raw Materials for 8 consecutive years, with $14.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Raw Materials fell 40.81% year-over-year to $14.2 million, compared with a TTM value of $14.2 million through Dec 2025, down 40.81%, and an annual FY2025 reading of $14.2 million, down 40.81% over the prior year.
  • Raw Materials was $14.2 million for Q4 2025 at Alnylam Pharmaceuticals, down from $22.3 million in the prior quarter.
  • Across five years, Raw Materials topped out at $65.2 million in Q3 2021 and bottomed at $14.2 million in Q4 2025.
  • Average Raw Materials over 5 years is $26.6 million, with a median of $22.6 million recorded in 2024.
  • The sharpest move saw Raw Materials tumbled 76.75% in 2021, then surged 51.25% in 2022.
  • Year by year, Raw Materials stood at $14.8 million in 2021, then skyrocketed by 51.25% to $22.3 million in 2022, then increased by 4.62% to $23.3 million in 2023, then grew by 2.65% to $24.0 million in 2024, then crashed by 40.81% to $14.2 million in 2025.
  • Business Quant data shows Raw Materials for ALNY at $14.2 million in Q4 2025, $22.3 million in Q3 2025, and $22.9 million in Q2 2025.